Common TitleLATTE
Official Title Phase IIb, Dose Ranging Study of Oral Cabotegravir (GSK1265744) in Combination With Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus -1 (HIV-1) Virologic Suppression Followed by an Evaluation of Maintenance of Virologic Suppression When Oral Cabotegravir (GSK1265744) is Combined With Oral Rilpivirine in HIV-1 Infected, Antiretroviral Therapy Naive Adult Subjects
Phase Phase IIB
ClinicalTrials.gov NCT01641809
Treatments
Injectable cabotegravir and Rilpivirine
Injectable cabotegravir and Rilpivirine
Tradename:CabenuvaClass:Long-Acting Injectable RegimensCategories Treatment-NaiveDual Therapy
Funding
IndustryViiV Healthcare
References
- Margolis DA, Brinson CC, Smith GH, et al. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial. Lancet Infect Dis. 2015;15:1145-55.